LONG-TERM EFFECTS OF OMEGA-3 POLYUNSATURATED FATTY ACIDS ON THE COURSE OF ISCHEMIC HEART DISEASE IN PATIENTS AFTER ST-ELEVATION MYOCARDIAL INFARCTION AT THE BACKGROUND OF MULTIPLE-VESSEL LESION CORONARY ATHEROSCLEROSIS

Currently there is enough evidence for that the use of omega-3-faty acids compounds in ischemic heart disease is followed by the decrease of mortality, and the efficacy of this usage in multivessel coronary lesions after primary percutaneous intervention (PCI) has not been studied.

Aim. To evaluate the efficacy of long-term intake of the omega-3-polyunsaturated fatty acids compounds on the course of ischemic heart disease at the background of multiple coronary lesion after primary PCI.

Material and methods. Totally 101 patient included at the age of 35-70 y.o., who had underwent primary PCI for the myocardial infarction with ST elevation and multiple vessel lesion of coronary arteries. The patients were selected into 2 groups: 1 group (n=68) — conservative tactics with the standard pharmacotherapy; 2nd group (n=33) — Omacor was added to the standard therapy.

Results. In 36 months of follow-up in the Omacor group there was significant decrease of repeated myocardial infarctions, decompensating heart failure, angina progression and rhythm disorders. In 2nd group patients during the 36-month follow-up a better antiischemic effect achieved with 80,9% decrease of angina from the baseline (p<0,047) and by 27,6% of the heart failure severity. The increase of exercise tolerance by the 6-minute walking test during 36 months was the highest in the 2nd group — by 65%.

Conclusion. Long-term prescription of omega-3-polyunsaturated fatty acids in ST elevation myocardial infarction with multiple vessel coronary lesions after primary PCI leads to the improvement of clinical condition, which then leads to the increase of exercise tolerance and better life quality. 

1. Aronov DM, Bubnova MG, Poghosova GV. The outpatient stage rehabilitation in patients with coronary heart disease. Heart 2005; 2: 103-7. Russian (Аронов Д.М., Бубнова М.Г., Погосова Г.В. Постстационарный этап реабилитации больных ишемической болезнью сердца. Сердце 2005; 2: 103-7).

2. Boqueria LA Makhaldiani ZB, Zhuravlev VA. State of the art medical treatment of atrial fibrillation. Annals arrhythmology 2006; 2: 5-17. Russian (Бокерия Л.А., Махалдиани З.Б., Журавлев В.А. Современное состояние проблемы медикамен- тозного лечения фибрилляции предсердий. Анналы аритмологии 2006; 2: 5-17).

3. Bucher HC, Hengstler P, Schindler C. N-3 polyunsaturated acids in coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med 2002; 112: 298-304.

4. Boqueria LA, Gudkov RG. Diseases and congenital malformations of the circulatory system. M.: Publishing House of the NTSSSH them. Bakulev RAMS 2009: 3-6. Russian (Бокерия Л.А., Гудкова Р.Г. Болезни и врожденные аномалии системы кровообращения. М.: Изд-во НЦССХ им. А.Н. Бакулева РАМН 2009: 3-6).

5. Gratsianskii NA, Erlich AD. Register acute coronary syndromes RECORD. Patients and treatment prior to discharge. Cardiology 2009; 7: 4-12. Russian (Грацианский Н.А, Эрлих А. Д. Регистр острых коронарных синдромов РЕКОРД. Характеристика больных и лечение до выписки из стационара. Кардиология 2009; 7: 4-12).

6. Oganov RG. Prevention of cardiovascular diseases in Russia: Successes, failures, and prospects. Therapeutic Archives 2004; 6: 22-4. Russian (Оганов Р.Г. Профилактика сердечно-сосудистых заболеваний в России: успехи, неудачи, перспективы. Тер архив 2004; 6: 22-4).

7. Boqueria LA, Babunashvili YI, Rabotnikov VS, et al. Acute coronary syndrome. Diagnosis and treatment. M.: Publishing house NTSSSH them. AN Bakuleva RAMS 2004: 286 p. Russian (Острый коронарный синдром. Возможности диагностики и лечения. Бокерия Л.А., Бабунашвили Ю.И., Работников В.С. и др. М.: Изд-во НЦССХ им. А.Н. Бакулева РАМН 2004: 286 c).

8. Akberov RF, Sharafeev AZ, Mikhailov MK, et al. Progressive multifocal atherosclerosis: etiology, clinical and radiologic diagnostics, modern aspects of treatment. Kazan: “Ideal-Press” 2008; 214. Russian (Прогрессирующий мультифокальный атеро- склероз: этиология, клинико-лучевая диагностика, современные аспекты лече- ния. Акберов Р.Ф., Шарафеев А.З., Михайлов М.К. и др. Казань: “Идеал-Пресс” 2008; 214).

9. АНА/АССF Secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular Disease: 2011 update: a Guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 2011; 124: 2458-73.

10. Chestukhin VV, Mironkov BL. Comparison of the effectiveness of percutaneous coronary intervention and optimal medical therapy in the treatment of stable form of coronary heart disease. Interventional cardiologists look at the problem and the results of research COURAGE. Heart 2007; 5: 265-8. Russian (Честухин В.В., Миронков Б. Л. Сравнение эффективности чрескожных коронарных вмеша- тельств и оптимальной медикаментозной терапии в лечении стабильной формы коронарной болезни сердца. Взгляд интервенционного кардиолога на пробле- му и результаты исследования COURAGE. Сердце 2007; 5: 265-8).

11. Bylov NA. The use of omega-3 polyunsaturated fatty acids in addition to the therapy of patients after myocardial infarction (Randomized Trial of Omega-3 Fatty Acidson Top of Modern Therapy). Heart 2011; 10 (1): 55-9. Russian (Былова Н.А. Применение омега-3-полиненасыщенных жирных кислот в дополнение к терапии пациентов, перенесших инфакт миокарда (Randomized Trial of Omega-3 Fatty Acidson Top of Modern Therapy). Сердце 2011; 10 (1): 55-9).

12. Kalyuzhin VV, Tepljakov AT, Kamaev DYu. Factors affecting the quality of life of patients after myocardial infarction. Cardiology 2001; 4: 58. Russian (Калюжин В.В., Тепляков А.Т., Камаев Д.Ю. Факторы, влияющие на качество жизни больных, перенесших инфаркт миокарда. В.В. Калюжин, Кардиология 2001; 4: 58).

13. GISSI-HF Investigators. Effects of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomized, double-blind, placebo￾conrolled trial. Lancet 2008; 372: 1223-30.

14. GISSI -Prevezione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevezione trial. Lancet 1999; 354: 447-55.

15. De Caterina R. N-3 fatty acids in cardiovascular diseases. N Eng J Med 2011; 364: 2439-50.

16. Finzi AA, Latini R, Barlera S, et al. Effects of n-3 polyunsaturated fatty acids on malignant ventricular arrithmias in patients with chronic heart failure and implantable cardioverter-defibrillation: a Substady GISSI-HF. Am Heart J 2011; 161: 338-43.

17. Tsaregorodcev DA, Gavva EM, Sulimov VA. Omega-3 polyunsaturated fatty acids in the treatment of cardio vascular system. Cardiology 2010; 8: 47-53. Russian (Царегородцев Д.А., Гавва Е.М., Сулимов В.А. Омега-3-полиненасыщенные жирные кислоты в лечении заболеваний сердечно-сосудистой системы. Кардиология 2010; 8: 47-53).

18. Marik PE, Varon J. Omega-3 dietary supplements and the risk of cardiovascular events: a systematic review. Clin Cardiol 2009; 32: 365-72.

19. Rauch B, Schiele R. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation 2010; 122: 2152-9.